Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|24|3896-3901

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.24, 2014-12, pp. : 3896-3901

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-enriched Sequencing in Chinese Patients with Advanced Non-small Cell Lung Cancer

By Jiang B   Liu F   Yang L   Zhang W   Yuan H   Wang J   Huang G  

The Journal of International Medical Research, Vol. 39, Iss. 4, 2011-07 ,pp. : 1392-1401

Field House Publishing

Access to resources Recommend Favorite

Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations

By Lin Chia-Chi   Yang James Chih-Hsin  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 79-88

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite